|
|
Volumn 97, Issue 3, 2006, Pages 438-439
|
|
The third analysis of the bicalutamide Early Prostate Cancer programme
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BICALUTAMIDE;
GONADORELIN AGONIST;
BONE DENSITY;
CANCER MORTALITY;
CARDIOTOXICITY;
CASTRATION;
CAUSE OF DEATH;
CLINICAL TRIAL;
DISEASE COURSE;
DISEASE FREE SURVIVAL;
DRUG EFFICACY;
DRUG SAFETY;
DRUG SUBSTITUTION;
DRUG TOLERABILITY;
EARLY CANCER;
EVALUATION;
GYNECOMASTIA;
HEART DEATH;
HOT FLUSH;
HUMAN;
LIBIDO;
MASTALGIA;
METASTASIS;
NOTE;
PRIORITY JOURNAL;
PROGNOSIS;
PROSTATE CANCER;
RISK BENEFIT ANALYSIS;
SEXUAL FUNCTION;
STANDARD;
ANDROGEN ANTAGONISTS;
ANILIDES;
ANTINEOPLASTIC AGENTS;
DATA INTERPRETATION, STATISTICAL;
DISEASE PROGRESSION;
DISEASE-FREE SURVIVAL;
HUMANS;
MALE;
PROSTATIC NEOPLASMS;
|
|
EID: 33645012490
PISSN: 14644096
EISSN: 1464410X
Source Type: Journal
DOI: 10.1111/j.1464-410X.2006.06118.x Document Type: Note |
|
Times cited : (11)
|
|
References (3)
|
